Themis Medicare Limited

Equities

THEMISMED

INE083B01024

Pharmaceuticals

Delayed Bombay S.E. 02:55:15 2024-04-18 am EDT 5-day change 1st Jan Change
209 INR +0.24% Intraday chart for Themis Medicare Limited -3.13% -1.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Themis Medicare Limited Launches REMITHEM CI
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Themis Medicare Limited Announces Incorporation of Wholly Owned Subsidiary CI
Themis Medicare Limited Announces Cessation of Vijay Agarwal as Independent Director CI
Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023 CI
Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Themis Medicare Limited Recommends Dividend for Financial Year Ended 31 March 2023 CI
Themis Medicare Limited Announces Board Resignations CI
Themis Medicare Gets Drug Controller General of India’s No-Objection for Diclofenac Injection MT
Themis Medicare Announces DCGI Approval of Remifentanil Hydrochloride 1mg/2mg for Injection for Import and Marketing CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Themis Medicare Launches Drug for Treatment of Menopausal Symptoms in India MT
Themis Medicare Ltd. Launches Lenzetto ¡Global Brand of Estradiol Novel Drug Delivery System CI
Themis Medicare Posts Decline in Fiscal Q2 Consolidated Profit MT
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Themis Medicare Limited entered into share purchase agreement to acquire additional 6.47% stake in Gujarat Themis Biosyn Limited from Pharmaceutical Business Group Limited for approximately INR 700 million. CI
Themis Medicare Partners with NFL Biosciences to Develop Anti-Smoking Drug in India MT
NFL Biosciences Partners with Themis Medicare for the Development of NFL-101 in India CI
Themis Medicare Limited Informs the Second Term of Office of Mr. Hoshang Sinor as Independent Director, Come to End CI
Themis Medicare Limited Declares Dividend for the Financial Year Ended March 31, 2022 CI
Themis Medicare Limited Announces Resignation of Lajos Kovacs as Board of Directors CI
Themis Medicare's Consolidated Profit Plummets in Fiscal Q1 MT
Chart Themis Medicare Limited
More charts
Themis Medicare Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).
More about the company
  1. Stock Market
  2. Equities
  3. THEMISMED Stock
  4. News Themis Medicare Limited
  5. Themis Medicare : CARE Raises Rating on Themis Medicare's Long-Term Bank Financing to B+; Outlook Stable